We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
Turnover
22.92%
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+38.53%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$524M
AUM Growth
+$84.8M
(+19%)
Cap. Flow
-$21.1M
Cap. Flow
% of AUM
-4.01%
Top 10 Holdings %
Top 10 Hldgs %
56.21%
Holding
96
New
14
Increased
18
Reduced
28
Closed
8
Avg Time Held
2.9
years
Top 10 Avg Time Held
2.4
years
Top 20 Avg Time Held
2.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$11.2M |
| 2 |
Denali Therapeutics
DNLI
|
+$8.64M |
| 3 |
Insulet
PODD
|
+$8.5M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$5.91M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$3.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Day One Biopharmaceuticals
DAWN
|
+$21M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$16.5M |
| 3 |
Biohaven
BHVN
|
+$7.62M |
| 4 |
MBX Biosciences
MBX
|
+$5.72M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$5.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.52% |
| 2 | Miscellaneous | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Tandem Diabetes Care
TNDM
$1.15B
| $5.36M | 1.02% |
355,208
| – | – |
2023 Q2
12 quarters
|
|
27
Alkermes
ALKS
$6.7B
| $5.31M | 1.01% |
101,266
-38,216
| -27% | -$1.49M |
2024 Q2
8 quarters
|
|
28
Stoke Therapeutics
STOK
$1.55B
| $4.28M | 0.82% |
130,875
| – | – |
2024 Q1
9 quarters
|
|
29
Allogene Therapeutics
ALLO
$449M
| $4.16M | 0.79% |
2,000,000
+629,882
| +46% | +$1.38M |
2024 Q2
8 quarters
|
|
30
BioCryst Pharmaceuticals
BCRX
$2.01B
| $4M | 0.76% |
400,248
-30,000
| -7% | -$271K |
2022 Q4
14 quarters
|
|
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.95B
| $3.9M | 0.74% |
130,175
| – | – |
2015 Q3
43 quarters
|
|
32
OrthoPediatrics
KIDS
$593M
| $3.62M | 0.69% |
189,130
+93,471
| +98% | +$1.62M |
2026 Q1
1 quarter
|
|
|
HELP
33
Helus Pharma Inc. Common Stock
HELP
$797M
| $3.4M | 0.65% |
514,061
+15,700
| +3% | +$78.5K |
2025 Q4
2 quarters
|
|
34
Rapport Therapeutics
RAPP
$1.36B
| $3.13M | 0.6% |
75,000
| – | – |
2025 Q3
3 quarters
|
|
35
Kymera Therapeutics
KYMR
$8.93B
| $3.1M | 0.59% |
+27,000
| New | +$2.32M |
2026 Q2
0 quarters
|
|
36
ProQR Therapeutics
PRQR
$202M
| $2.85M | 0.54% |
1,530,361
-37,200
| -2% | -$61.3K |
2023 Q1
13 quarters
|
|
37
Neurogene
NGNE
$474M
| $2.8M | 0.53% |
89,032
+32,397
| +57% | +$892K |
2024 Q2
8 quarters
|
|
38
Adlai Nortye Group ADS
ANL
$775M
| $2.75M | 0.53% |
+239,553
| New | +$2.91M |
2026 Q2
0 quarters
|
|
39
Procept Biorobotics
PRCT
$1.06B
| $2.71M | 0.52% |
120,000
| – | – |
2025 Q4
2 quarters
|
|
40
Aquestive Therapeutics
AQST
$508M
| $2.69M | 0.51% |
645,915
+277,500
| +75% | +$1.17M |
2024 Q1
9 quarters
|
|
41
Celldex Therapeutics
CLDX
$2.25B
| $2.55M | 0.49% |
68,518
| – | – |
2025 Q3
3 quarters
|
|
42
Structure Therapeutics
GPCR
$1.56B
| $2.5M | 0.48% |
46,500
| – | – |
2024 Q2
8 quarters
|
|
43
Align Technology
ALGN
$10.7B
| $2.36M | 0.45% |
14,000
-1,000
| -7% | -$174K |
2024 Q4
6 quarters
|
|
44
Viking Therapeutics
VKTX
$3.41B
| $2.32M | 0.44% |
59,516
| – | – |
2018 Q4
30 quarters
|
|
45
NervGen Pharma
NGEN
$176M
| $2.16M | 0.41% |
+1,050,000
| New | +$3.26M |
2026 Q2
0 quarters
|
|
|
46
Biohaven
BHVN
$1.69B
| $2.05M | 0.39% |
137,593
-708,142
| -84% | -$7.62M |
2022 Q3
15 quarters
|
|
47
Maze Therapeutics
MAZE
$1.53B
| $1.94M | 0.37% |
65,000
+30,000
| +86% | +$786K |
2026 Q1
1 quarter
|
|
48
Alector
ALEC
$228M
| $1.83M | 0.35% |
908,351
| – | – |
2021 Q3
19 quarters
|
|
49
Lexeo Therapeutics
LXEO
$225M
| $1.76M | 0.33% |
377,059
| – | – |
2024 Q3
7 quarters
|
|
50
Profound Medical
PROF
$230M
| $1.73M | 0.33% |
260,360
-2,645
| -1% | -$17.8K |
2025 Q4
2 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, DAFNA Capital Management held 96 positions worth $524M, up 19% from $440M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
DAFNA Capital Management withdrew a net $21.1M in Q2 2026, closing 8 positions and reducing 28 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in NervGen Pharma worth $2.16M.
- DAFNA Capital Management's largest Q2 2026 buy was NervGen Pharma: 1,050,000 shares worth $2.16M.
- DAFNA Capital Management added most to Nektar Therapeutics in Q2 2026, an estimated $11.2M increase.
- DAFNA Capital Management's biggest Q2 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $16.5M.
- DAFNA Capital Management fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $21M.
- DAFNA Capital Management's ten largest holdings make up 56% of its $524M portfolio in Q2 2026.
- DAFNA Capital Management opened 14 new positions and closed 8 in Q2 2026.
- DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $524M.
Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.